Brief: Abbvie Says Tepkinly In Combination With Lenalidomide And Rituximab Approved By European Commission
06/07/2026 19:31
BRIEF-Abbvie Says Tepkinly In Combination With Lenalidomide And Rituximab Approved By European Commission July 6 (Reuters) - Abbvie Inc ABBV.N:
ABBVIE ANNOUNCES TEPKINLY® (EPCORITAMAB) IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IS APPROVED BY THE EUROPEAN COMMISSION FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Source text: ID:nPre4Dr5Ga
Further company coverage: ABBV.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbbVie
See all newsBrief: Abbvie Reaches Agreement With The Pan-Canadian Pharmaceutical Alliance (Pcpa) For Elahere® In Platinum-Resistant Ovarian Cancer
Eli Lilly hits record high as healthcare stocks rally
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96